Veradermics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for skin diseases. The company's primary focus is on addressing significant unmet medical needs in the treatment of viral skin infections, such as molluscum contagiosum and common warts. Veradermics' lead product candidate, VD-101, is a proprietary, stable, and standardized topical formulation of cantharidin. This candidate is being developed for the treatment of molluscum contagiosum, a common and highly contagious viral skin infection that primarily affects children and currently lacks widely approved, painless, and effective treatments. The company's approach combines specialized drug delivery technology with established active pharmaceutical ingredients to improve safety, efficacy, and the overall patient experience. By targeting pediatric and adult populations suffering from contagious skin conditions, Veradermics aims to capture a significant share of the dermatology market. The company is led by a management team with extensive experience in clinical development and regulatory pathways within the pharmaceutical sector, focusing on advancing its clinical programs to bring therapeutic solutions to the global market.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!